Dr Reddy's Laboratories on Friday reported a 33.02 per cent increase in consolidated profit after tax at Rs 1,482.2 crore in the second quarter ended September 30, led by the US generics market.

Source: https://indianexpress.com/article/business/companies/dr-reddys-q2-results-net-profit-rises-revenue-jumps-9002179/

Elite Pharmaceuticals): Elite’s recent US FDA review nod positions it for a generics market surge.

Source: https://investorplace.com/2023/11/7-penny-stocks-with-promising-potential-catalysts-in-2024/

They’re the medicines that doctors currently use to treat patients, and they’re often generics.

Source: https://krdo.com/news/2023/09/12/cancer-experts-demand-action-to-end-ongoing-drug-shortage-peoples-lives-are-really-at-stake/

Within generics, 88 abbreviated new drug applications ("ANDAs") are pending with the FDA, and there are 78 pipeline products.

Source: https://seekingalpha.com/article/4657032-amneal-pharmaceuticals-by-most-measures-a-fundamentally-undervalued-company?source=feed_all_articles